There are dozens of candidates still in the race to produce a vaccine for COVID-19 around the world. But one of Canada’s leading contenders—developed at the University of Alberta by oncology researcher John Lewis and his team at Entos Pharmaceuticals—is showing promising early results.
John Lewis holds the Frank and Carla Sojonky Chair in Prostate Cancer Research funded by the Alberta Cancer Foundation, and is a member of the Cancer Research Institute of Northern Alberta (CRINA).
